IFOSFAMIDE


Trade Names	IFEX IFOSFAMIDE
Synonyms	Ifex Ifosfamide Ifsofamide Isophosphamide MJF 9325 MJF-9325 Mitoxana NSC-109724 Z-4942 Z4942
Status
Molecule Category	Free-form
ATC	L01AA06
UNII	UM20QQM95Y
EPA CompTox	DTXSID7020760


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HOMGKSMUEGBAAB-UHFFFAOYSA-N
Smiles	O=P1(NCCCl)OCCCN1CCCl
InChI	InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C7H15Cl2N2O2P
Molecular Weight	261.09
AlogP	1.88
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	41.57
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	14.0

Pharmacology

Mechanism of Action	Action	Reference
DNA inhibitor	INHIBITOR	DailyMed

Related Entries

Cross References

Resources	Reference
ChEBI	5864
ChEMBL	CHEMBL1024
DrugBank	DB01181
DrugCentral	1421
FDA SRS	UM20QQM95Y
Human Metabolome Database	HMDB0015312
Guide to Pharmacology	7201
KEGG	C07047
PharmGKB	PA449964
PubChem	3690
SureChEMBL	SCHEMBL4885

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).